Oncogenic HER2 fusions in gastric cancer

BACKGROUND: Genetic amplification of HER2 drives tumorigenesis and cancer progression in a subset of patients with gastric cancer (GC), and treatment with trastuzumab, a humanized HER2-neutralizing antibody, improves the overall survival rate of HER2-positive patients. However, a considerable portio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, De-Hua, Tang, Lili, Dong, Hua, Dong, Zhengwei, Zhang, Lianhai, Fu, Jiangang, Su, Xinying, Zhang, Tianwei, Fu, Haihua, Han, Lu, Xie, Liang, Chen, Hao, Qian, Ziliang, Zhu, Guanshan, Wang, Jia, Ye, Qingqing, Zhang, Jingchuan, Yin, Xiaolu, Zhang, Xiaolin, Ji, Jiafu, Ji, Qunsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396883/
https://www.ncbi.nlm.nih.gov/pubmed/25889497
http://dx.doi.org/10.1186/s12967-015-0476-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396883/
https://www.ncbi.nlm.nih.gov/pubmed/25889497
http://dx.doi.org/10.1186/s12967-015-0476-2

Ejemplares similares